L&K Bio Reports Q1 Operating Profit of 1.7 Billion KRW, Up 102% Year-on-Year
LNKBioMed announced on the 16th that it recorded sales of 9.1 billion KRW, operating profit of 1.7 billion KRW, and net profit of 1.8 billion KRW on a consolidated basis for the first quarter of this year.
Compared to the same period last year, sales increased by 18% and operating profit by 102%. This is the highest quarterly performance since LNKBioMed was listed on the KOSDAQ market in 2016.
A company representative explained, "The long-standing litigation issue was resolved through settlement, eliminating litigation-related costs, and the increased recognition of the PassLock-TM product in the U.S. along with aggressive marketing efforts have driven the performance."
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
LNKBioMed has achieved 1,800 PassLock-TM surgeries this month. This is three times faster than the time taken to reach 500 surgeries.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
